Efficacy and Safety of Rituximab in the Treatment of Idiopathic Membranous Nephropathy: A Meta-Analysis

Background. Primary membranous nephropathy (MN), sometimes referred to as idiopathic membranous nephropathy (IMN), is a kind of MN whose pathogenesis is yet unclear. According to research reports, the incidence of IMN is about 9.8–26.8%, and it is on the rise. Methods. The computer retrieves eight d...

Full description

Saved in:
Bibliographic Details
Published in:Applied bionics and biomechanics 2022-10, Vol.2022, p.1-9
Main Authors: Lu, Huijuan, Shen, Jun, Sun, Jieqiong, Sun, Jia
Format: Article
Language:English
Subjects:
Analysis
Antigens
Autoimmune diseases
B cells
Care and treatment
Creatinine
Data analysis
Development and progression
Immunotherapy
Information management
Kidney diseases
Medical research
Membranous nephropathy
Meta-analysis
Monoclonal antibodies
Nephropathy
Pathogenesis
Quality assessment
Remission (Medicine)
Review
Rituximab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. Primary membranous nephropathy (MN), sometimes referred to as idiopathic membranous nephropathy (IMN), is a kind of MN whose pathogenesis is yet unclear. According to research reports, the incidence of IMN is about 9.8–26.8%, and it is on the rise. Methods. The computer retrieves eight databases to obtain controlled trials at home and abroad on the rituximab (RTX) actions in IMN management. After a rigorous literature quality evaluation, software called RevMan 5.3 was used for data analysis. Results. This meta-analysis finally contained 8 papers. They were all regarded as controlled trials. Six studies reported serum creatinine (standardized mean difference [SMD]: −6.87; 95% CI: −14.09, 0.35; P=0.062), ALB (SMD: 1.91; 95% CI: −0.31, 4.14; P=0.092), and adverse reactions (OR: 0.56; 95% CI: 0.36, 0.90; P
ISSN:1176-2322
1754-2103
DOI:10.1155/2022/5393797